BRD4 and prostate carcinoma: This phosphorylation enhances the recruitment of p300 and BRD4, releasing P-TEFb and maintaining AR target gene transcription.384 Inhibition of AR signaling, is standard treatment for advanced prostate cancer, but resistance often develops, leading to castration-resistant prostate cancer (CRPC).